Unless there were any known reasons at the time as to why CureVac wouldn't be able to create a functioning vaccine, I'm not sure how it's any use to anybody to take this position. There are no sure bets. There are going to be failures. That shouldn't be reason to stop funding companies like this if they otherwise show they're capable. I'd say Germany has more issues around being too conservative and playing it too safe than taking too many risky bets.

If we didn't have the other vaccines, getting 47% efficiency for a billion euros would have been an awesome result. We could have also stopped the pandemic with a 47% effective vaccine. We're just spoiled because the vaccine development efforts did so well in general that 90%+ is now our standard.

They were the most promising vaccine company at one point. So promising that Trump tried to buy them.

Eh, BioNTech got about half a billion from the Germany govt. You win some, you lose some.

Like, should the German government have had its on-staff wizards look into the future to decide which on the face of it very similar mRNA vaccine to fund? They funded two, one worked well and hundreds of millions of doses have been administered. That seems like reasonable value for money, to be honest.

> I'm sure the German tax payers are delighted.

We really are, thanks for assuming.